文献速递主动脉疾病

二甲双胍使用与肾下腹主动脉瘤EVAR术后长期结局及瘤囊动态的回顾性研究

Metformin Use and Long-term Outcomes Including Aneurysm Sac Dynamics Following EVAR for Infrarenal Abdominal Aortic Aneurysm: "A Retrospective Study".
PubMed 文献 · J Endovasc Ther · 2024-08-14

荷兰一家学术医院2000—2022年685例择期标准EVAR的肾下腹主动脉瘤患者中,51例(7%)术前使用二甲双胍、634例(93%)未使用。二甲双胍对EVAR术后瘤囊体积随时间变化、8年全因死亡及免于移植物相关事件均未见显著影响。作者认为二甲双胍对腹主动脉瘤的潜在保护作用在EVAR后可能不再持续,需进一步前瞻性研究。

要点

  • 二甲双胍对EVAR术后瘤囊体积随时间变化的影响不显著(-3.9 cc/年,95%CI:-22.7,14.9;p=0.685)。
  • 风险校正后,二甲双胍组与未使用组全因死亡率相似(50% vs 44%;HR=1.11,95%CI:0.66,1.88;p=0.688)。
  • 免于移植物相关事件二甲双胍组63% vs 未使用组66%(HR=1.82,95%CI:0.98,3.38;p=0.059)。

核心结论

  • 二甲双胍使用可能减少术前腹主动脉瘤增长,但似乎不影响EVAR术后整体/长期瘤囊动态、全因死亡率或免于移植物相关事件。
  • 作者认为二甲双胍对腹主动脉瘤的潜在保护作用在EVAR后可能不再持续,需进一步前瞻性研究探究其在EVAR后腹主动脉瘤管理中的潜在作用机制。

研究设计与样本

  • 回顾性研究,纳入2000—2022年在荷兰一家学术医院因肾下腹主动脉瘤接受择期标准EVAR的患者。
  • 共分析685例,其中非二甲双胍使用者634例(93%),二甲双胍使用者51例(7%);二甲双胍使用定义为EVAR前使用。
  • 收集基线人口学、合并症、解剖与手术特征及术后30天事件;主要结局为术后瘤囊体积随时间变化,采用线性混合效应模型分析。
  • 次要结局为8年全因死亡与免于移植物相关事件,采用Kaplan-Meier法评估。

主要发现

  • 中位随访时间相似:二甲双胍组4.0年(IQR=1.5,6.5)vs 非二甲双胍组5.0年(IQR=2.0,8.0);p=0.091。
  • 术前瘤囊体积:二甲双胍组153 cc(IQR=114,195)vs 非二甲双胍组178 cc(IQR=133,240);p=0.054。
  • EVAR术后30天,二甲双胍组平均瘤囊体积与非二甲双胍组相当(二甲双胍:-19.4 cc,95%CI:-47.4,8.5;p=0.173)。
  • 二甲双胍对瘤囊随时间增长的影响不显著(-3.9 cc/年,95%CI:-22.7,14.9;p=0.685)。
  • 风险校正后,二甲双胍使用与相似的全因死亡率相关(二甲双胍 vs 未使用:50% vs 44%;HR=1.11,95%CI:0.66,1.88;p=0.688),免于移植物相关事件(二甲双胍 vs 未使用:63% vs 66%;HR=1.82,95%CI:0.98,3.38;p=0.059)。

临床怎么用

  • 作者认为二甲双胍对腹主动脉瘤的潜在保护作用在EVAR后可能不再持续,并强调需在该领域持续开展研究。

局限性

  • 原文为回顾性研究。
  • 研究在荷兰一家学术医院单中心开展。
  • 二甲双胍使用者仅51例(7%),样本量小。
  • 作者指出需进一步前瞻性研究以探究二甲双胍在EVAR后腹主动脉瘤管理中的潜在作用机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metformin, widely used for the treatment of diabetes mellitus (DM), has shown potential for inhibiting abdominal aortic aneurysm (AAA) growth by reducing extracellular matrix remodeling and inflammation. However, its influence on clinical outcomes and aneurysm sac dynamics after endovascular aneurysm repair (EVAR) remains uncertain. This retrospective study aims to explore the effects of metformin on long-term outcomes following EVAR. MATERIALS AND METHODS: Patients who underwent elective standard EVAR for infrarenal AAA at a single academic Dutch hospital from 2000 to 2022 were included. We collected baseline patient demographics, comorbid conditions, anatomical and operative characteristics, and 30-day postoperative events. Metformin use was defined as using it preceding EVAR. The primary outcome, the postoperative aneurysm sac volume over time, was investigated using linear mixed-effects modeling. The secondary outcomes, 8-year all-cause mortality and freedom from graft-related events, were evaluated using Kaplan-Meier methods. RESULTS: We analyzed 685 patients, including 634 (93%) non-metformin users and 51 (7%) metformin users. The median follow-up period was similar (4.0 years [IQR=1.5, 6.5] vs 5.0 years [IQR=2.0, 8.0]; p=0.091). Patients on metformin had a preoperative aneurysm sac volume of 153 cc (IQR=114, 195) compared with 178 cc (IQR=133, 240) for non-metformin patients (p=0.054). At 30 days post-EVAR, metformin patients had a comparable mean aneurysm sac volume compared with non-metformin patients (metformin: -19.4 cc [95% confidence interval [CI]: -47.4, 8.5]; p=0.173). The effect of metformin on aneurysm growth over time was not significant (-3.9 cc/year; [95% CI: -22.7, 14.9]; p=0.685). Following risk-adjusted analysis, metformin use was associated with similar rates of all-cause mortality (metformin vs no metformin: 50% vs 44%; hazard ratio [HR]=1.11, 95% CI: 0.66, 1.88; p=0.688) and freedom from graft-related events (metformin vs no metformin: 63% vs 66%; HR=1.82, 95% CI: 0.98, 3.38; p=0.059). CONCLUSION: Although metformin use may reduce preoperative AAA growth, it does not seem to influence overall/long-term post-EVAR AAA sac dynamics, all-cause mortality, or freedom from graft-related events. These findings suggest that the potential protective effect of metformin on AAA may not be sustained after EVAR. Further prospective studies are needed to investigate the mechanisms underlying the potential role of metformin in AAA management following EVAR.Clinical ImpactThere is currently no approved pharmacological treatment available to slow the abdominal aortic aneurysm (AAA) growth rate and reduce the related risk of rupture. In our retrospective analysis including 685 patients undergoing EVAR for infrarenal AAA, we found that metformin use was not associated with improved post-EVAR outcomes, such as a reduction of aneurysm sac volume over time, eight-year all-cause mortality, or freedom of graft-related events. These findings suggest that the potential protective effect of metformin on AAA may not be sustained after EVAR and underscore the need for ongoing research into this area.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. van Tongeren OLRM, Rastogi V, Vecht DE, et al. Metformin Use and Long-term Outcomes Including Aneurysm Sac Dynamics Following EVAR for Infrarenal Abdominal Aortic Aneurysm: "A Retrospective Study". J Endovasc Ther. 2024. PMID: 39140336. doi:10.1177/15266028241268500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。